 |
|
Home | AstraZeneca Receives “Buy” Rating from UBS AG (AZN) |
 |
AstraZeneca Receives “Buy” Rating from UBS AG (AZN)
|
 |
- May 30, 2013
-
AstraZeneca (LON: AZN)‘s stock had its “buy” rating reaffirmed by investment analysts at UBS AG in a note issued to investors on Thursday, ARN reports. They currently have a GBX 3,600 ($54.47) price target on the stock. UBS AG’s target price indicates a potential upside of 4.24% from the stock’s previous close. AstraZeneca (LON: AZN) [...]This article (AstraZeneca Receives “Buy” Rating from UBS AG (AZN)) was originally developed by and is property of American Banking News.
Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.
- Read more at:http://www.americanbankingnews.com/2013/05/30/astrazeneca-receives-buy-rating-from-ubs-ag-azn-2/
|
 |
|
 |
|
 |
